Stocksigma LogoStocksigma Logo

Gujarat Kidney and Super Speciality Limited Reports Robust Q2 FY27 Financial Results

Gujarat Kidney and Super Speciality reported a 194.6% YoY jump in Q2 FY27 revenue from operations to ₹3,809 lakhs (+11.1% QoQ), with PAT rising 129.4% YoY

Gujarat Kidney and Super Speciality Limited Reports Robust Q2 FY27 Financial Results

Gujarat Kidney and Super Speciality Ltd · Investor Presentation · 05 Nov 2026, 3:30 am

Gujarat Kidney and Super Speciality Limited Reports Robust Q2 FY27 Financial Results Gujarat Kidney and Super Speciality reported a 194.6% YoY jump in Q2 FY27 revenue from operations to ₹3,809 lakhs (+11.1% QoQ), with PAT rising 129.4% YoY to ₹660 lakhs (+24.0% QoQ). EBITDA climbed 99.4% YoY to ₹1,022 lakhs, with margins expanding 239 bps QoQ to 26.8%. H1 FY27 revenue reached ₹7,238 lakhs, representing 88% of FY26 full-year revenue. The company maintains a net-cash balance sheet with ₹1,488 lakhs in net cash and deployed ₹1,669 lakhs toward H1 acquisitions, expanding across Gujarat and entering Dubai via Blue Tree Clinics.

Original exchange filing (PDF)

More announcements from Gujarat Kidney and Super Speciality Ltd

All Gujarat Kidney and Super Speciality Ltd announcements